Insider Transactions in Q3 2024 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,352
-2.85%
|
$88,224
$12.19 P/Share
|
|
Sep 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+5.71%
|
-
|
|
Aug 23
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,135
-2.49%
|
$25,620
$12.4 P/Share
|
|
Aug 23
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,916
-2.19%
|
$22,992
$12.4 P/Share
|
|
Aug 22
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.5%
|
-
|
|
Aug 22
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.44%
|
-
|
|
Aug 19
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,102
-7.76%
|
$85,224
$12.01 P/Share
|
|
Aug 19
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
14,215
-5.54%
|
$170,580
$12.01 P/Share
|
|
Aug 19
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,973
-8.97%
|
$95,676
$12.01 P/Share
|
|
Aug 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,495
+11.15%
|
-
|
|
Aug 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,195
+10.52%
|
-
|
|
Aug 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,528
+17.25%
|
-
|